# Does New York Medicaid Cover Wegovy or Zepbound? NYRx's BMI 40 and Lifetime Limits By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-11-06 Canonical page: https://glpwatchdog.org/research/new-york-medicaid-glp1-coverage > New York's NYRx excludes GLP-1s for weight loss yet pays for Wegovy in heart disease and Zepbound in sleep apnea. The BMI 40 line, the two-attempt lifetime limit, the forms' six-month requirements, the diabetes list, the missing MASH route and the 60-day hearing window. ## Key points - NYRx calls weight loss a use Medicaid has never covered, and that stays the rule. - Wegovy for established heart disease and Zepbound for sleep apnea both need a BMI of 40 or more. - Each drug is capped at two treatment attempts per lifetime for its covered use. - The forms ask for six months of lifestyle change, plus heart therapy for Wegovy or CPAP and a sleep test for Zepbound. - We found no MASH route, and a state regulation gives 60 days to request a fair hearing. Not for weight loss. NYRx, New York’s Medicaid drug program, excludes GLP-1s for weight loss, but as of November 2026 it covers Wegovy for established cardiovascular disease and Zepbound for moderate to severe sleep apnea.[1] Both routes require prior authorization and a BMI of at least 40, and both stop at two treatment attempts in a lifetime.[4][5][6] > **About this article.** This page reads the NYRx drug list, coverage overviews and prior authorization forms as of November 1, 2026, along with state regulations. For the federal rule behind state choices, see [why Medicaid treats Ozempic and Wegovy differently](https://glpwatchdog.org/research/does-medicaid-cover-ozempic-and-wegovy). ## Does NYRx cover Wegovy or Zepbound for weight loss? No. The program’s overview says bluntly that Medicaid in New York has never covered weight loss as a use.[2] States may leave weight-loss agents out under federal law, and New York’s regulation refuses payment for a drug whose sole clinical use is weight reduction.[3][11] The NYRx overview names Ozempic, Wegovy and Mounjaro as excluded for that purpose.[2] A diagnosis of obesity alone will not open either route. New York moved its pharmacy benefit from managed care to NYRx, so these rules, more than a health plan’s formulary, are the place to start.[9] Check with the program if your coverage is unusual, such as a plan type outside regular Medicaid. ## What does NYRx require for Wegovy and Zepbound? *NYRx prior authorization rules from the overviews, drug list and forms read November 1, 2026* | | Wegovy | Zepbound | | --- | --- | --- | | Covered use | Reducing major heart events with established cardiovascular disease | Moderate to severe obstructive sleep apnea | | BMI | At least 40 | At least 40 | | Lifetime limit | Two treatment attempts | Two treatment attempts | | Before starting | Six months on prescribed heart therapy; six months of comprehensive lifestyle change | CPAP tried or in use; sleep study or home test; nutrition referral; six months of lifestyle change | | Renewal | No lapses in use; still on heart therapy; lifestyle change continues | No lapses in use; lifestyle change continues | The forms also ask about diabetes and bar a second GLP-1 at the same time.[7][8] Each form gives a space for a clinical reason when a requirement cannot be met, such as why CPAP is not appropriate. NYRx says it answers faxed requests within 24 hours.[7][8] ## Why is the BMI 40 line so important? It sits far above the label. Wegovy’s heart use takes in adults with cardiovascular disease who carry excess weight of either grade, and SELECT, the trial behind it, enrolled people from a BMI of 27.[13][15] Zepbound’s sleep apnea use covers adults with obesity, which generally begins at a BMI of 30.[14] So someone with a prior heart attack and a BMI of 38 meets the label and misses the New York test. For contrast, [Texas Medicaid’s Wegovy route](https://glpwatchdog.org/research/texas-medicaid-glp1-coverage) accepts an overweight diagnosis. One wording point matters if your BMI is right at 40. The Wegovy overview dated July 2026 says above 40, while the drug list revised October 22, 2026 says 40 or more.[4][6] Ask the NYRx clinical call center which applies. The form records BMI at the start of therapy, so someone moving from another insurer can report that starting figure.[7][8] ## What does two treatment attempts per lifetime mean? NYRx counts how many times you have tried the drug for that use, and a third attempt calls for a clinical reason on the form.[4][5][7][8] The documents do not define exactly what ends an attempt. The renewal questions treat adherence as consistent use with no lapses, including under a previous insurer, so a long gap is the event to discuss with your prescriber before it happens.[7][8] If you need to pause for a reason such as surgery or a side effect, ask how NYRx would count it, and have your prescriber write down the reason at the time. ## Does NYRx cover Wegovy for MASH? We found no route. The September 21, 2026 overview lists three covered uses (type 2 diabetes, heart events and sleep apnea), and the drug list row for Wegovy names cardiovascular disease only.[1][6] Wegovy’s label does include noncirrhotic MASH with moderate to advanced fibrosis, so a prescriber can raise it with the clinical call center.[13] Our guide to [GLP-1s for fatty liver](https://glpwatchdog.org/research/glp1-and-fatty-liver-mash) covers the trial evidence. ## Does New York Medicaid cover Ozempic, Mounjaro and other diabetes GLP-1s? Yes, for type 2 diabetes. On the October 22, 2026 list, exenatide, the Ozempic pen, Trulicity and Victoza are preferred. Generic liraglutide, Mounjaro, Ozempic tablets, Rybelsus and the insulin combinations Soliqua and Xultophy are non-preferred.[6] Preferred drugs can pay at the pharmacy without a prior authorization when the claim history already shows a qualifying diagnosis, so your prescriber should send diagnosis codes with claims.[2] Non-preferred drugs need one.[2] NYRx will also reject a second GLP-1 or a second strength until 25% or less of the current fill remains, which can catch people moving up a dose early.[2] ## What about members under 21? The NYRx overviews set no separate pediatric route. Federal child-health rules require Medicaid to provide necessary treatment to people under 21 whether or not the state plan covers it.[12] Wegovy’s label reaches obesity from age 12.[13] We found no New York document applying that duty to GLP-1s, so a family facing a refusal should ask for a medical necessity review under EPSDT by name and be ready to request a hearing. ## How do you appeal an NYRx denial? Start with the prior authorization itself, since a missing document can be fixed by resubmitting. If the request is still refused, New York’s fair hearing rule gives 60 days after the agency’s determination, action or failure to act.[10] Your notice controls, so follow its date and instructions if they differ. An appeal has the most to work with when it argues your facts fit a covered use: a sleep study result, six months of heart medicines or a documented reason you cannot use CPAP. A case built on the BMI line or on weight loss itself has much less, and the forms warn that false statements carry False Claims Act penalties.[8] Our guide to [prior authorization and appeals](https://glpwatchdog.org/research/glp1-prior-authorization-and-appeals) shows what to include, and the [Medicaid Zepbound explainer](https://glpwatchdog.org/research/does-medicaid-cover-zepbound) covers the federal hearing rights. ## What can you do if you don't qualify? Older weight-loss pills are unlikely to help here. New York’s regulation pays for amphetamine-like substances only for conditions other than obesity or weight reduction, which is the group phentermine belongs to, and it appears nowhere on the list we searched.[3][6] Our [phentermine and GLP-1 comparison](https://glpwatchdog.org/research/phentermine-vs-a-glp1) is useful if you are weighing it at your own cost. Lilly’s savings card for insured patients excludes Medicaid enrollees.[16] Self-pay prices in the figures we track are $349 a month for most Wegovy pen doses from Novo Nordisk, and $299 at the starting dose, $399 at 5 mg and $449 at 7.5 mg and up for Lilly’s Zepbound KwikPen or vial, when each refill comes within 45 days.[16][17] Read each offer’s terms for government-program limits. Our list of [GLP-1 prices without insurance](https://glpwatchdog.org/research/cheapest-glp1-without-insurance) compares the routes. ## Frequently asked questions ### Does New York Medicaid cover Wegovy? Only for established cardiovascular disease, as of November 2026. NYRx requires prior authorization, a BMI of at least 40, six months on heart therapy and six months of lifestyle change, with a limit of two treatment attempts per lifetime. It does not cover Wegovy for weight loss. ### Does NYRx cover Zepbound for sleep apnea? Yes, as of a July 2026 overview, for moderate to severe sleep apnea in people with obesity. The request needs a BMI of at least 40, a CPAP trial or current use or a reason it is not appropriate, a sleep study or home test, a nutrition referral and six months of lifestyle change. ### Does New York Medicaid cover Ozempic? Yes, for type 2 diabetes. The Ozempic pen is a preferred drug on the NYRx list and can pay without prior authorization when the claim history shows a qualifying diagnosis. Ozempic tablets are non-preferred. NYRx does not cover it for weight loss. ### What does two treatment attempts per lifetime mean on NYRx? NYRx limits Wegovy and Zepbound to two tries each for the covered use. A later attempt requires a clinical reason on the prior authorization form. The documents do not define when an attempt ends, so ask the NYRx clinical call center before pausing therapy. ### How long do I have to appeal an NYRx denial? New York's regulation gives 60 days after the agency's determination, action or failure to act to request a fair hearing. Follow the date and steps on your own notice if they differ, and consider asking your prescriber to resubmit if the problem is missing paperwork. ## References 1. NYRx, the Medicaid Pharmacy Program (Prime Therapeutics State Government Solutions) NYRx Coverage Overview of Glucagon Like Peptide-1 Receptor Agonists, September 21, 2026. newyork.fhsc.com. 2026. https://newyork.fhsc.com/downloads/providers/NYRx_EO_notification_Glucagon_Like_Peptide.pdf 2. NYRx, the Medicaid Pharmacy Program NYRx Drug Class Coverage Overview: GLP-1 Receptor Agonists, Type 2 Diabetes, revised July 16, 2026. newyork.fhsc.com. 2026. https://newyork.fhsc.com/downloads/providers/NYRx_EO_notification_20230913.pdf 3. State of New York 18 NYCRR §505.3: Prescription drugs. Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/regulations/new-york/18-NYCRR-505.3 4. NYRx, the Medicaid Pharmacy Program NYRx Drug Coverage Overview: Wegovy, July 16, 2026, revised July 23, 2026. newyork.fhsc.com. 2026. https://newyork.fhsc.com/downloads/providers/NYRx_EO_notification_wegovy.pdf 5. NYRx, the Medicaid Pharmacy Program NYRx Drug Coverage Overview: Zepbound, July 30, 2026. newyork.fhsc.com. 2026. https://newyork.fhsc.com/downloads/providers/NYRx_EO_notification_zepbound.pdf 6. NYRx, the Medicaid Drug Program NYRx Preferred Drug List, revised October 22, 2026. newyork.fhsc.com. 2026. https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf 7. NYRx, the Medicaid Pharmacy Program Wegovy Prior Authorization Request Form, revised October 30, 2025. newyork.fhsc.com. 2025. https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PA_Worksheet_Prescribers_Wegovy.pdf 8. NYRx, the Medicaid Pharmacy Program Zepbound Prior Authorization Request Form, revised July 14, 2026. newyork.fhsc.com. 2026. https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PA_Worksheet_Prescribers_Zepbound.pdf 9. NYRx, the Medicaid Pharmacy Program NYRx program site, including the Pharmacy Benefit Transition from Managed Care to NYRx listing. newyork.fhsc.com. 2026. https://newyork.fhsc.com/ 10. State of New York 18 NYCRR §358-3.5: Right to a fair hearing, how to request a hearing. Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/regulations/new-york/18-NYCRR-358-3.5 11. United States Code 42 U.S.C. §1396r-8: Payment for covered outpatient drugs (Social Security Act §1927). Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/uscode/text/42/1396r-8 12. United States Code 42 U.S.C. §1396d: Definitions, including early and periodic screening, diagnostic and treatment services. Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/uscode/text/42/1396d 13. Novo Nordisk WEGOVY (semaglutide): prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b 14. Eli Lilly and Company ZEPBOUND (tirzepatide) injection: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b 15. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023. PMID: 37952131. DOI: 10.1056/NEJMoa2307563. https://pubmed.ncbi.nlm.nih.gov/37952131/ 16. Eli Lilly and Company Zepbound savings and self-pay options, with card terms. zepbound.lilly.com. 2026. https://zepbound.lilly.com/savings 17. Novo Nordisk Wegovy savings offer. novocare.com. 2026. https://www.novocare.com/obesity/products/wegovy/savings-offer.html --- Cite as: GLP Watchdog, Nora Bissett, "Does New York Medicaid Cover Wegovy or Zepbound? NYRx's BMI 40 and Lifetime Limits", published 2026-11-06. https://glpwatchdog.org/research/new-york-medicaid-glp1-coverage Canonical HTML page: https://glpwatchdog.org/research/new-york-medicaid-glp1-coverage Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.